Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:04:43时区推断·⟳ 抓取 19:10:36·⚡ 决策 08-04 22:59:51 +3h49m·83.9 天前
Beam Therapeutics完成risto-cel镰状细胞病试验成人及青少年患者给药并重申2026年底递交BLA计划
本次最正面的增量是BEACON成人及青少年患者完成给药，但BLA最快2026年底递交、现金 runway 至2029年中等核心叙事此前已多次披露。
📄 原文Investing.com↗ 原文
Beam Therapeutics completes dosing in sickle cell trial
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets CAMBRIDGE, Mass. - Beam Therapeutics Inc. (NAS…
不做 Beam Therapeutics（BEAM.US）
不做：这是财报日管线进展汇总，完成给药偏正面但BLA时间表和主要临床叙事已多次披露，且没有新增疗效数据、监管获批或可量化商业增量；Q2亏损扩大也不支持短线追多。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Investing.com盘前转述Beam Q2财报与管线进展，核心新增为BEACON成人及青少年患者完成给药。
- 公司此前已披露risto-cel BEACON数据、成人及青少年队列已在2025年中完成入组、所有剂量制造已在2025年12月完成，并重申2026年底最早递交BLA。
- 公司已提前宣布BEAM-302将在2026年9月ERS以late-breaking形式更新数据，本次财报再次提及该节点不构成新数据读出。
关键理由
- 本次最正面的增量是BEACON成人及青少年患者完成给药，但BLA最快2026年底递交、现金 runway 至2029年中等核心叙事此前已多次披露。
- 商业化量级仍停留在预期阶段：risto-cel尚未获批、无销售收入；公司TTM收入约1.4亿至1.6亿美元、当前价值主要来自临床管线期权，本次没有新增疗效数据或监管获批来显著改变估值。
- Q2净亏损扩大至1.227亿美元、每股亏损1.18美元，虽有12亿美元现金支撑但不是短线利好财报 surprise。
主要风险
- 若年底前更新数据显著优于同类SCD基因疗法或FDA审评路径进一步加速，当前不做可能错过后续临床数据催化。
- 当前信号是财报日管线进展汇总，缺少新疗效读数、批准或可量化销售增量，盘中追BEAM容易变成交易旧预期。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-01-11 · 影响 weakens
BLA最快2026年底递交和现金 runway 至2029年的框架早在1月战略更新中已经出现，削弱本次作为新催化的预期差。
检索:Beam Therapeutics risto-cel BLA expected year-end 2026 January 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-04 · 影响 weakens
市场此前预期Q2亏损约每股1.00至1.11美元，信号披露的每股亏损1.18美元不支持财报追多。
检索:Beam Therapeutics Q2 2026 EPS consensus August 4 2026 原文 ↗
原文全文
展开原文 · 2,275 字
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
CAMBRIDGE, Mass. - Beam Therapeutics Inc. (NASDAQ:BEAM) completed dosing for all adult and adolescent patients in its Phase 1/2 BEACON trial evaluating risto-cel for sickle cell disease, according to a press release statement issued Tuesday.
The biotechnology company expects to submit a biologics license application for risto-cel as early as year-end 2026 and plans to report updated trial data by the end of the year.
Beam dosed the first patient in July in the global pivotal cohort of its Phase 1/2 trial for BEAM-302, a therapy for alpha-1 antitrypsin deficiency. The cohort is designed to support a potential accelerated approval path in the United States. Updated clinical data for BEAM-302 was selected for a late-breaking oral presentation at the European Respiratory Society Congress, scheduled for September 5-9, 2026, in Barcelona, Spain.
The U.S. Food and Drug Administration cleared the investigational new drug application for BEAM-304 in phenylketonuria in June. The company has initiated clinical start-up activities for a planned Phase 1/2 trial that will initially evaluate safety, tolerability and reduction of blood phenylalanine levels in patients with the R408W mutation.
The company completed enrollment and dosing in the Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody. Treatment was well tolerated across all doses tested, according to the statement.
Beam reported cash, cash equivalents and marketable securities of $1.2 billion as of June 30, 2026. The company expects these funds, together with an additional $200 million expected to be drawn from its facility with Sixth Street, will support operating plans into mid-2029.
For the second quarter of 2026, research and development expenses were $95.1 million, compared to $101.8 million in the same period last year. General and administrative expenses were $31.9 million, compared to $26.9 million in the second quarter of 2025.
Net loss was $122.7 million, or $1.18 per share, compared to a net loss of $102.1 million, or $1.00 per share, in the second quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CAMBRIDGE, Mass. - Beam Therapeutics Inc. (NASDAQ:BEAM) completed dosing for all adult and adolescent patients in its Phase 1/2 BEACON trial evaluating risto-cel for sickle cell disease, according to a press release statement issued Tuesday.
The biotechnology company expects to submit a biologics license application for risto-cel as early as year-end 2026 and plans to report updated trial data by the end of the year.
Beam dosed the first patient in July in the global pivotal cohort of its Phase 1/2 trial for BEAM-302, a therapy for alpha-1 antitrypsin deficiency. The cohort is designed to support a potential accelerated approval path in the United States. Updated clinical data for BEAM-302 was selected for a late-breaking oral presentation at the European Respiratory Society Congress, scheduled for September 5-9, 2026, in Barcelona, Spain.
The U.S. Food and Drug Administration cleared the investigational new drug application for BEAM-304 in phenylketonuria in June. The company has initiated clinical start-up activities for a planned Phase 1/2 trial that will initially evaluate safety, tolerability and reduction of blood phenylalanine levels in patients with the R408W mutation.
The company completed enrollment and dosing in the Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody. Treatment was well tolerated across all doses tested, according to the statement.
Beam reported cash, cash equivalents and marketable securities of $1.2 billion as of June 30, 2026. The company expects these funds, together with an additional $200 million expected to be drawn from its facility with Sixth Street, will support operating plans into mid-2029.
For the second quarter of 2026, research and development expenses were $95.1 million, compared to $101.8 million in the same period last year. General and administrative expenses were $31.9 million, compared to $26.9 million in the second quarter of 2025.
Net loss was $122.7 million, or $1.18 per share, compared to a net loss of $102.1 million, or $1.00 per share, in the second quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。